Latest Articles and Analysis

The Centers for Disease Control and Prevention (CDC) released its National HIV Prevention and Care Objectives: 2026 Update on May 18, 2026, presenting the most recent national picture of the U.S. HIV...

On May 4, 2026, Health Secretary Robert F. Kennedy Jr. closed a daylong Make America Healthy Again (MAHA) Institute summit on mental health and overmedicalization by announcing a federal initiative...

On March 6, 2026, the Iowa Department of Health and Human Services filed a nine-page complaint in Polk County District Court alleging that NuCara Specialty Pharmacy failed to remit more than $22...

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

States are rationing HIV medications through prior auth and formulary cuts to solve ADAP budget crises — a strategy that costs more, drives resistance, and concentrates harm on the most vulnerable.

ADAPs achieve 87% viral suppression but face funding crisis as multiple policies erode 340B rebates.

Medicare drug negotiation's third wave includes Biktarvy, raising HIV treatment access concerns.

Administration expands OUD medication access while defunding SAMHSA and restricting harm reduction.

Q1 2026 Watch: HCV/HIV co-infection treatment access under evolving federal and state policies.

Florida ADAP cuts eligibility from 400% to 130% FPL, threatening 16,000 PLWHA.

HIV care system deterioration from administrative obstruction and funding delays presages catastrophic effects of potential budget cuts.

Federal policy changes including Medicaid work requirements and ADAP eligibility restrictions threaten access to HIV medications.

Q4 2025 Watch monitoring HCV treatment access and federal initiatives including Cure Hepatitis C Act.

Q3 2025 Watch: critical analysis including Cure Hepatitis C Act proposing subscription treatment models.

Impending HIV care crisis results from Medicaid work requirements, federal funding cuts, and healthcare system fragmentation.

Ukraine's integrated addiction care model outperforms U.S. fragmented approach despite war devastation and resource constraints.

Q2 2025 Watch monitoring HCV and HIV treatment access through ADAPs, Medicaid, and federal assistance.

Copay accumulator programs exclude patient assistance from deductibles, creating barriers to medication adherence and treatment.

Q1 2025 Watch: comprehensive update on HIV/HCV co-infection treatment access across federal and state programs.

DoxyPEP post-exposure prophylaxis demonstrates effectiveness for STI prevention with implementation challenges and equity concerns.